Walleye Capital
SRPT icon

Walleye Capital’s Sarepta Therapeutics SRPT Stock Holding History

Walleye Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$619K Sell
34,421
-254,111
-88% -$4.81M ﹤0.01% 2535
2026
Q1 		$6.28M Buy
288,532
+15,800
+6% +$306K 0.03% 656
2025
Q4 		$5.87M Buy
272,732
+115,952
+74% +$2.44M 0.02% 1021
2025
Q3 		$3.02M Sell
156,780
-279,445
-64% -$4.98M 0.01% 1280
2025
Q2 		$7.46M Buy
436,225
+423,278
+3,269% +$18.1M 0.03% 645
2025
Q1 		$826K Buy
12,947
+8,515
+192% +$896K ﹤0.01% 2130
2024
Q4 		$539K Sell
4,432
-5,453
-55% -$668K ﹤0.01% 2917
2024
Q3 		$1.23M Sell
9,885
-25,777
-72% -$3.56M ﹤0.01% 2422
2024
Q2 		$5.63M Sell
35,662
-4,317
-11% -$555K 0.01% 1202
2024
Q1 		$5.18M Sell
39,979
-68,862
-63% -$8.44M 0.01% 1268
2023
Q4 		$10.5M Buy
108,841
+67,073
+161% +$6.43M 0.02% 643
2023
Q3 		$5.06M Buy
41,768
+31,032
+289% +$3.51M 0.01% 1033
2023
Q2 		$1.23M Sell
10,736
-9,593
-47% -$1.24M ﹤0.01% 1680
2023
Q1 		$2.8M Sell
20,329
-27,340
-57% -$3.55M 0.04% 538
2022
Q4 		$6.18M Buy
+47,669
New +$5.52M 0.11% 225
2022
Q2 		– Sell
-53,361
Closed -$4.17M – 2707
2022
Q1 		$4.17M Buy
53,361
+31,488
+144% +$2.41M 0.11% 192
2021
Q4 		$1.97M Buy
21,873
+17,626
+415% +$1.51M 0.06% 328
2021
Q3 		$393K Buy
+4,247
New +$327K 0.01% 895
2021
Q2 		– Sell
-11,282
Closed -$841K – 1500
2021
Q1 		$841K Buy
+11,282
New +$1.04M 0.05% 368
2019
Q3 		– Sell
-11,111
Closed -$1.31M – 2246
2019
Q2 		$1.69M Buy
+11,111
New +$1.35M 0.19% 134

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Walleye Capital's SRPT Position: Q2 2026 in Review

Walleye Capital reduced its Sarepta Therapeutics (SRPT) stake by 88% in Q2 2026, selling an estimated $4.81M and leaving 34,421 shares worth $619K. The position accounts for ﹤0.01% of the portfolio, ranked #2535.

Walleye Capital first reported a position in SRPT in Q2 2019 and has held it in 20 quarters since. The position peaked at $10.5M in Q4 2023. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Walleye Capital held 34,421 shares of Sarepta Therapeutics worth $619K as of Q2 2026.
  • Walleye Capital sold 254,111 Sarepta Therapeutics shares in Q2 2026, an estimated $4.81M.
  • Sarepta Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2535 holding.
  • Walleye Capital first reported a position in Sarepta Therapeutics in Q2 2019 and has held it in 20 quarters since.
  • Walleye Capital's Sarepta Therapeutics position peaked at $10.5M in Q4 2023.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.